Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $3.00 Price Target at Mizuho

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price objective reduced by Mizuho from $4.00 to $3.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. A number of other equities research analysts have also weighed in on the company. The Goldman Sachs Group […]

Related Keywords

United States ,Canada ,Gina Mazzariello ,Joshuab Cohen ,Robertw Baird ,Qube Research Technologies Ltd ,Amylyx Pharmaceuticals ,Amylyx Pharmaceuticals Inc ,Amylyx Pharmaceuticals Stock Performance ,News Ratings For Amylyx Pharmaceuticals Daily ,Institutional Trading Of Amylyx Pharmaceuticals ,Rafferty Asset Management ,Analyst Recommendations For Amylyx Pharmaceuticals ,Path Wealth Partners ,Goldman Sachs Group ,Securities Exchange Commission ,Nasdaq ,Free Report ,Get Free Report ,Exchange Commission ,Asset Management ,Technologies Ltd ,Amylyx Pharmaceuticals Daily ,Nasdaq Amlx ,Amlx ,Medical ,Lower Price Target ,Mizuho ,